Neuralink raises $650 million Series E
Evidence notes
- ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners and Vy Capital participated.
- Neuralink linked the financing to broader access for people with unmet medical needs and continued brain-interface development.
- At the announcement, Neuralink reported five people with severe paralysis using its technology and clinical trials spanning the United States, Canada and the UAE.
Company context
Neuralink develops implantable brain-computer interfaces and the R1 surgical robot used to place ultra-fine electrode threads.